Prefilled Auto Injectors Market Size, Share, Industry, Forecast and Outlook (2024-2031)

Global Prefilled Auto-Injectors Market Size, Share & Trends Analysis Report By Application, By Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2024 – 2031

Prefilled Auto-Injectors Market Overview

The global prefilled auto-injectors market reached US$ XX million in 2023 and is expected to reach US$ XX million by 2031, growing at a CAGR of XX% during the forecast period 2024-2031. 

Auto-injectors are the devices that are used to accurately deliver the drug in the patient's body, making drug delivery convenient. There are two types of auto-injectors which are cartridge-based and pre-filled ones. Pre-filled auto-injectors basically contain single doses of drugs that were pre-filled and readily available for administration. Currently, there are several pre-filled auto-injectors approved and commercially sold. The notable examples are EpiPen which is used for the treatment of anaphylaxis, Humira, Rosuvo, Orencia, and SIMPONI for the treatment of several auto-immune conditions. There are several other pre-filled auto-injectors used in migrane and diabetes. 

The rising investments in product development, advancements in drug delivery, and rising preference for self-administration of drugs for chronic conditions are the factors that are expected to strongly drive the market growth in the forecast period. 

Prefilled Auto-Injectors Market  Scope

For more details on this report - Request for Sample

Prefilled Auto-Injectors Market Dynamics: Drivers

Rising pipeline development and approval of products

Autoinjectors right from their invention have revolutionized drug delivery, especially the delivery of biopharmaceuticals. These autoinjectors have become a solution for complex problems such as precise dosing, needle phobia, safety in the context of drugs with narrow margin of safety especially biologic drugs, etc. They offer several advantages over conventional drug delivery and have attained greater attention in recent times. Currently, over 300 million pre-filled auto-injectors are sold annually and several companies have been actively focussing on the development of pre-filled auto-injectors for their drugs, some of which have recently got approval for marketing authorization by the regulatory bodies are some are currently in the development phase. This continuous innovation and expansion of the pre-filled auto-injector portfolio is expected to drive the global market in the forecast period. 

For instance, in February 2023, the US Food and Drug Administration (FDA) approved Tezspire (tezepelumab) a pre-filled auto-injector developed by AstraZeneca and Amgen. Tezspire is commercially launched in the U.S. for use in severe asthmatic patients. 

In December 2023, the U.S. Food and Drug Administration (FDA) approved UDENYCA ONBODY a prefilled auto-injector for the treatment of infections after cancer chemotherapy.  UDENYCA is a pegfilgrastim biosimilar approved in the U.S. and has treated approximately 300,000 patients since its launch in 2019. 

Also in May 2023, the U.S. Food and Drug Administration (FDA) approved the Cyltezo Pen developed by Boehringer Ingelheim International GmbH. The FDA had already approved Cyltezo (adalimumab-adbm) which is a biosimilar of Humira in the form of a pre-filled syringe and is indicated for the treatment of multiple types of chronic inflammatory conditions. 

In addition, factors such as rising preference for self-medication, and rising technological advancements in drug delivery are expected to boost the market growth in the forecast period.

Restraints

The high cost of prefilled auto-injectors is one of the restraining factors that may hinder market growth. Affordability plays a crucial role when a new product should be adopted in the market. Chronic patients in low-middle-income nations may not have access to these advanced drug delivery devices. In addition, patient compliance and adherence issues may pose a significant challenge to the market growth which may cause lower adoption of the devices. 

Prefilled Auto-Injectors Market Segment Analysis

The global prefilled auto-injectors market is segmented based on application, distribution channel and region.

The autoimmune conditions in the application segment accounted for approximately 45.2% of the global prefilled auto-injectors market share

Autoimmune diseases are those conditions in which the body’s immune system attacks its cells. There are several types of autoimmune conditions and the commonest ones are rheumatoid arthritis, type 1 diabetes, Crohn’s disease, thyroid conditions, psoriasis, etc. There are several drugs that are approved for the treatment of these auto-immune conditions and the notable one is Humira (adalimumab) which is indicated for rheumatoid arthritis, juvenile idiopathic arthritis (JIA), psoriatic arthritis, ankylosing spondylitis, IBD, uveitis etc. Humira is available in single-dose-prefilled auto-injectors. Likewise, several other top-selling prefilled auto-injectors are indicated for the treatment of auto-immune conditions. 

For example, below is the list of top-selling prefilled auto-injectors whose indications are autoimmune conditions

Prefilled Auto-Injectors Market Geographical Analysis 

North America is expected to dominate the market with a 43.2% share in the global prefilled auto-injectors market

North America is expected to dominate the market due to its well-advanced healthcare infrastructure, and state-of-the-art hospitals equipped with high-end technologies. Moreover, the the major high-income countries in the region the U.S. and Canada are well-known for their investments in the healthcare industry. The majority of the manufacturers of prefilled auto-injectors have a stronghold market share in these regions which is a strong contributing factor to the region’s dominance in the global market.

For instance, the market share of top-selling pre-filled auto-injectors in North America is as follows:

Prefilled Auto-Injectors Market Segmentation

By Application

• Anaphylaxis
• Migraine
• Diabetes
• Orthopedic Conditions
• Autoimmune Conditions
• Others

By Route of Administration

• Subcutaneous
• Intra-Muscular

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Rest of Europe
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Middle East and Africa

Prefilled Auto-Injectors Market Competitive Landscape

The major players in the prefilled auto-injectors market include Teva Pharmaceuticals USA, Inc., Viatris Inc., Medexus Pharma, Inc., ALK-Abelló Ltd, Novo Nordisk A/S, Bausch Health, Canada Inc., GSK plc., Eli Lilly and Company, AbbVie. and UCB, Inc. among others. 

Why Purchase the Report?

• To visualize the global prefilled auto-injectors market segmentation based on application, route of administration, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of prefilled auto-injectors market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global prefilled auto-injectors market report would provide approximately 62 tables, 54 figures, and 187 Pages.

Target Audience 2024

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies